NCT06757140View on ClinicalTrials.gov

Opioid Drug Interaction Study

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

January 1, 2029

Study Completion Date

June 1, 2029

Conditions
Drug InteractionsDrug Kinetics
Interventions
DRUG

Alprazolam

Participants will receive varying non-therapeutic experimental doses of oral alprazolam, alone and in combination with oral oxycodone

DRUG

Oxycodone

Participants will receive varying non-therapeutic experimental doses of oral oxycodone, alone and in combination with oral alprazolam

DRUG

Placebo

Participants will receive inactive oral doses

Trial Locations (1)

40508

RECRUITING

University of Kentucky, Lexington

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Shanna Babalonis, PhD

OTHER